US 11,951,114 B2
Use of thyroid beta-agonists
Brian Lian, San Diego, CA (US); Rochelle Hanley, Ann Arbor, MI (US); Misha Dinerman, Cincinnati, OH (US); Mark Erion, Brookline, MA (US); Serge Boyer, San Diego, CA (US); and Hongjian Jiang, Shanghai (CN)
Assigned to Viking Therapeutics, Inc., San Diego, CA (US); and Metabasis Therapeutics, Inc., San Diego, CA (US)
Filed by Viking Therapeutics, Inc., San Diego, CA (US); and Metabasis Therapeutics, Inc., San Diego, CA (US)
Filed on May 6, 2022, as Appl. No. 17/738,621.
Application 17/738,621 is a continuation of application No. 16/095,228, granted, now 11,351,183, previously published as PCT/US2017/029120, filed on Apr. 24, 2017.
Claims priority of provisional application 62/326,436, filed on Apr. 22, 2016.
Prior Publication US 2022/0257618 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/662 (2006.01)
CPC A61K 31/662 (2013.01) 6 Claims
 
1. A method for treating X-linked adrenoleukodystrophy, comprising administering to a subject a compound selected from:

OG Complex Work Unit Chemistry
or a salt or ester thereof.